Abbott Laboratories Stock Price Target and Analyst Ratings (NYSE:ABT)

Analyst Price Target for ABT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$121.83

▼ -0.45% Downside Potential

This price target is based on 17 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $121.83, with a high forecast of $140.00 and a low forecast of $94.00. The average price target represents a -0.45% upside from the last price of $122.38.

Buy

The current consensus among 17 contributing investment analysts is to buy stock in Abbott Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
15 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

9/3/2019

0 strong buy ratings
13 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

12/2/2019

0 strong buy ratings
14 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

3/1/2020

0 strong buy ratings
15 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

5/30/2020

0 strong buy ratings
12 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

8/28/2020

0 strong buy ratings
14 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

11/26/2020

0 strong buy ratings
14 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
15 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

2/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/28/2021	Wells Fargo & Company	Boost Price Target		$128.00 ➝ $137.00	Medium	i
1/28/2021	Cowen	Boost Price Target	Outperform	$113.00 ➝ $140.00	Medium	i
1/28/2021	Credit Suisse Group	Boost Price Target	Outperform	$118.00 ➝ $130.00	High	i
1/28/2021	Morgan Stanley	Boost Price Target	Overweight	$126.00 ➝ $136.00	High	i
1/28/2021	SVB Leerink	Boost Price Target	Market Perform	$115.00 ➝ $128.00	High	i
1/28/2021	Raymond James	Boost Price Target	Outperform	$114.00 ➝ $126.00	High	i
1/28/2021	BTIG Research	Upgrade	Neutral ➝ Buy	$140.00	High	i
12/15/2020	Morgan Stanley	Boost Price Target	Overweight	$121.00 ➝ $126.00	Low	i
11/19/2020	Morgan Stanley	Boost Price Target	Overweight	$117.00 ➝ $121.00	Low	i
10/22/2020	Jefferies Financial Group	Boost Price Target	Buy	$113.00 ➝ $123.00	High	i
10/22/2020	Credit Suisse Group	Lower Price Target	Outperform	$136.00 ➝ $118.00	High	i Rating by Matt Miksic at Credit Suisse Group AG
10/22/2020	Raymond James	Boost Price Target	Market Perform ➝ Outperform	$102.00 ➝ $114.00	High	i
10/22/2020	Morgan Stanley	Boost Price Target	Overweight	$112.00 ➝ $117.00	High	i
10/22/2020	SVB Leerink	Boost Price Target	Positive ➝ Market Perform	$110.00 ➝ $115.00	High	i
10/9/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$110.00 ➝ $125.00	Low	i
10/7/2020	Wells Fargo & Company	Boost Price Target	Overweight	$120.00 ➝ $122.00	Low	i Rating by Larry Biegelsen at Wells Fargo & Company
9/11/2020	Wolfe Research	Initiated Coverage	Outperform	$124.00	Low	i
9/2/2020	The Goldman Sachs Group	Set Price Target	Sell	$94.00	Low	i Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/31/2020	Credit Suisse Group	Boost Price Target	Outperform	$109.00 ➝ $136.00	Low	i Rating by Matt Miksic at Credit Suisse Group AG
8/28/2020	Citigroup	Boost Price Target	Buy	$110.00 ➝ $130.00	High	i
8/27/2020	BTIG Research	Reiterated Rating	Hold		High	i Rating by Marie Thibault at BTIG Research
8/27/2020	The Goldman Sachs Group	Set Price Target	Sell	$94.00	Medium	i Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/27/2020	Wells Fargo & Company	Boost Price Target		$107.00 ➝ $115.00	Medium	i Rating by Larry Biegelsen at Wells Fargo & Company
8/27/2020	Stifel Nicolaus	Boost Price Target	Buy	$108.00 ➝ $115.00	Low	i
8/27/2020	Morgan Stanley	Boost Price Target	Overweight	$106.00 ➝ $112.00	Medium	i
7/23/2020	Argus	Boost Price Target		$110.00 ➝ $125.00	Low	i
7/20/2020	Bank of America	Boost Price Target	Buy	$95.00 ➝ $110.00	Medium	i
7/17/2020	SVB Leerink	Boost Price Target	Market Perform	$97.00 ➝ $110.00	High	i
7/17/2020	Morgan Stanley	Boost Price Target	Overweight	$100.00 ➝ $106.00	High	i
7/17/2020	Credit Suisse Group	Boost Price Target	Outperform	$106.00 ➝ $109.00	High	i Rating by Matt Miksic at Credit Suisse Group AG
7/17/2020	Citigroup	Boost Price Target	Buy	$109.00 ➝ $110.00	Medium	i
7/9/2020	Wells Fargo & Company	Reiterated Rating	Buy	$107.00	Low	i Rating by Larry Biegelsen at Wells Fargo & Company
6/25/2020	Morgan Stanley	Lower Price Target	Overweight	$108.00 ➝ $100.00	High	i
5/31/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$84.00	Medium	i
5/22/2020	Credit Suisse Group	Reiterated Rating	Buy	$106.00	Low	i Rating by Matt Miksic at Credit Suisse Group AG
4/20/2020	Barclays	Boost Price Target	Overweight	$92.00 ➝ $100.00	Medium	i
4/17/2020	UBS Group	Boost Price Target	Buy	$105.00 ➝ $109.00	Low	i
4/17/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$88.00 ➝ $98.00	Low	i
4/17/2020	Stifel Nicolaus	Boost Price Target		$85.00 ➝ $108.00	Low	i
4/17/2020	Credit Suisse Group	Boost Price Target	Outperform	$95.00 ➝ $106.00	Medium	i Rating by Matt Miksic at Credit Suisse Group AG
4/17/2020	Raymond James	Boost Price Target	Overweight ➝ Outperform	$92.00 ➝ $102.00	Low	i
4/17/2020	Citigroup	Boost Price Target	Buy	$87.00 ➝ $109.00	Medium	i
4/17/2020	Wells Fargo & Company	Boost Price Target	Overweight	$95.00 ➝ $107.00	Medium	i
4/16/2020	BTIG Research	Reiterated Rating	Hold		Low	i Rating by Marie Thibault at BTIG Research
4/16/2020	Cfra	Boost Price Target	Buy	$99.00 ➝ $101.00	Low	i
4/9/2020	Wells Fargo & Company	Boost Price Target	Overweight	$92.00 ➝ $95.00	Medium	i
4/9/2020	Raymond James	Lower Price Target	Outperform	$99.00 ➝ $92.00	Medium	i
4/8/2020	Wells Fargo & Company	Reiterated Rating	Buy		Medium	i
4/8/2020	SVB Leerink	Lower Price Target	Market Perform	$102.00 ➝ $93.00	High	i
4/3/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$101.00 ➝ $88.00	Low	i
3/30/2020	Wells Fargo & Company	Reiterated Rating	Buy		Medium	i
3/27/2020	Citigroup	Lower Price Target	Buy	$96.00 ➝ $87.00	Medium	i
3/27/2020	Morgan Stanley	Lower Price Target	Overweight	$101.00 ➝ $96.00	Medium	i
3/6/2020	Credit Suisse Group	Lower Price Target	Outperform	$104.00 ➝ $94.00	High	i
3/4/2020	Citigroup	Initiated Coverage	Buy	$96.00	Medium	i
2/12/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$96.00	Low	i
2/6/2020	BTIG Research	Reiterated Rating	Hold		Low	i
1/23/2020	JPMorgan Chase & Co.	Lower Price Target		$96.00 ➝ $101.00	Low	i
1/23/2020	UBS Group	Boost Price Target	Buy	$99.00 ➝ $105.00	Low	i
1/23/2020	Wells Fargo & Company	Boost Price Target	Overweight	$97.00 ➝ $103.00	Medium	i
1/23/2020	Raymond James	Boost Price Target	Outperform	$90.00 ➝ $99.00	Medium	i
1/23/2020	Stifel Nicolaus	Boost Price Target	Buy	$95.00 ➝ $104.00	Medium	i
1/2/2020	Citigroup	Downgrade	Neutral ➝ Sell		High	i
1/2/2020	Evercore ISI	Downgrade	Outperform ➝ In-Line		High	i
1/2/2020	Guggenheim	Downgrade	Buy ➝ Neutral		Medium	i
12/17/2019	Morgan Stanley	Boost Price Target	Overweight	$93.00 ➝ $101.00	Medium	i
10/17/2019	William Blair	Reiterated Rating	Underperform		Low	i Rating by M. Kaczor at William Blair
10/17/2019	Credit Suisse Group	Boost Price Target	Outperform	$95.00 ➝ $98.00	Low	i
10/14/2019	Raymond James	Lower Price Target	Outperform	$93.00 ➝ $90.00	Low	i
7/18/2019	Jefferies Financial Group	Boost Price Target	Buy	$80.00 ➝ $98.00	Medium	i
7/18/2019	Cowen	Boost Price Target	Outperform	$86.00 ➝ $95.00	High	i
7/18/2019	Raymond James	Boost Price Target	Outperform	$87.00 ➝ $93.00	Medium	i
7/18/2019	BMO Capital Markets	Boost Price Target	Outperform	$87.00 ➝ $94.00	Medium	i
7/16/2019	Morgan Stanley	Boost Price Target	Overweight	$85.00 ➝ $93.00	Low	i
6/13/2019	Bank of America	Reiterated Rating	Buy	$81.00	Low	i
6/13/2019	Wells Fargo & Company	Boost Price Target	Outperform	$89.00 ➝ $91.00	Low	i
4/18/2019	William Blair	Reiterated Rating	Outperform		N/A	i Rating by M. Kaczor at William Blair
4/15/2019	Royal Bank of Canada	Boost Price Target	Buy	$82.00	Low	i
3/14/2019	Wells Fargo & Company	Reiterated Rating	Buy		High	i
3/8/2019	Barclays	Set Price Target	Buy	$84.00	Low	i Rating by Kristen Stewart at Barclays PLC
2/7/2019	Bank of America	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $81.00	Low	i
1/25/2019	Argus	Boost Price Target	Buy ➝ In-Line	$90.00	Low	i
1/24/2019	BTIG Research	Reiterated Rating	Hold		Medium	i
1/2/2019	Gabelli	Reiterated Rating	Buy		Low	i Rating by J. Tsai at Gabelli
1/2/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$82.00 ➝ $85.00	Low	i
1/2/2019	Citigroup	Downgrade	Neutral ➝ Sell	$72.00 ➝ $68.00	High	i
12/17/2018	Credit Suisse Group	Initiated Coverage	Outperform	$82.00	Low	i
12/9/2018	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$74.10	Low	i Rating by Issac Ro at The Goldman Sachs Group, Inc.
12/4/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $82.00	High	i
11/30/2018	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$78.00 ➝ $81.00	Low	i Rating by Isaac Ro at The Goldman Sachs Group, Inc.
11/27/2018	UBS Group	Initiated Coverage	Buy	$83.00	High	i
10/18/2018	Jefferies Financial Group	Reiterated Rating	In-Line ➝ Buy	$80.00	High	i
10/18/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $79.00	High	i
10/18/2018	BTIG Research	Reiterated Rating	Hold		High	i
10/15/2018	Barclays	Initiated Coverage	Overweight ➝ Overweight	$80.00	High	i
10/11/2018	Morgan Stanley	Boost Price Target	Overweight	$70.00 ➝ $80.00	Medium	i
10/11/2018	Royal Bank of Canada	Boost Price Target	Outperform	$77.00	Low	i
10/8/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$77.00 ➝ $81.00	Low	i
10/5/2018	Cowen	Boost Price Target	Outperform ➝ Average	$72.00 ➝ $86.00	Low	i
9/24/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$72.00 ➝ $77.00	Medium	i
9/24/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $80.00	Medium	i
7/19/2018	Royal Bank of Canada	Reiterated Rating	Buy	$70.00	Low	i
7/19/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$71.00 ➝ $72.00	Medium	i
6/27/2018	Sanford C. Bernstein	Initiated Coverage	Outperform	$73.00	Medium	i
4/24/2018	Citigroup	Lower Price Target	Neutral ➝ Neutral	$66.00 ➝ $65.00	Low	i
4/22/2018	BTIG Research	Reiterated Rating	Hold		Low	i
1/30/2018	Argus	Boost Price Target	Buy	$66.00 ➝ $80.00	Low	i
1/30/2018	Citigroup	Boost Price Target	Neutral ➝ Neutral	$59.00 ➝ $64.00	Low	i
1/25/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$66.00 ➝ $70.00	Low	i
1/25/2018	Guggenheim	Reiterated Rating	Buy	$72.00	Low	i
1/25/2018	Royal Bank of Canada	Reiterated Rating	Buy	$67.00	Low	i
1/25/2018	SVB Leerink	Reiterated Rating	Market Perform	$60.00 ➝ $68.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
1/25/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$65.00 ➝ $69.00	High	i
1/25/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $70.00	High	i
1/25/2018	Wells Fargo & Company	Boost Price Target	Outperform	$66.00 ➝ $70.00	Medium	i
1/25/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$65.00 ➝ $70.00	Medium	i
1/25/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $71.00	Medium	i
1/25/2018	William Blair	Upgrade	Market Perform ➝ Outperform		Medium	i Rating by M. Kaczor at William Blair
1/24/2018	Bank of America	Boost Price Target		$60.00 ➝ $70.00	High	i
1/22/2018	BTIG Research	Downgrade	Buy ➝ Neutral		Medium	i
1/19/2018	SVB Leerink	Reiterated Rating	Market Perform		Low	i Rating by D. Antalffy at SVB Leerink LLC
1/9/2018	Royal Bank of Canada	Reiterated Rating	Buy	$65.00	Low	i
1/8/2018	Barclays	Reiterated Rating	Buy	$66.00	Low	i
1/3/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$64.00	Low	i
1/2/2018	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$60.00 ➝ $60.00	Low	i
1/2/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$67.00	Low	i
12/12/2017	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$58.00 ➝ $65.00	Medium	i
10/19/2017	Barclays	Reiterated Rating	Overweight		N/A	i
10/19/2017	Citigroup	Reiterated Rating	Neutral		N/A	i
10/19/2017	BMO Capital Markets	Reiterated Rating	Market Perform		N/A	i
10/19/2017	Cowen	Set Price Target	Buy	$55.00 ➝ $68.00	N/A	i
10/19/2017	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $63.00	N/A	i
10/19/2017	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$55.00 ➝ $60.00	N/A	i
10/19/2017	Jefferies Financial Group	Reiterated Rating	Buy	$65.00	N/A	i
10/6/2017	JPMorgan Chase & Co.	Initiated Coverage	Neutral ➝ Neutral	$60.00	N/A	i
10/4/2017	Bank of America	Reiterated Rating	Buy	$56.00 ➝ $60.00	N/A	i
10/3/2017	Royal Bank of Canada	Reiterated Rating	Buy	$55.00	Low	i
10/2/2017	BMO Capital Markets	Reiterated Rating	Hold	$53.00	Low	i
9/28/2017	Barclays	Boost Price Target	Overweight	$57.00 ➝ $60.00	Low	i
9/28/2017	Wells Fargo & Company	Boost Price Target	Outperform	$57.00 ➝ $64.00	Low	i
9/24/2017	Cowen	Reiterated Rating	Buy		Low	i Rating by Josh Jennings at Cowen Inc
9/1/2017	BMO Capital Markets	Reiterated Rating	Hold	$53.00	N/A	i
8/17/2017	Citigroup	Initiated Coverage	Neutral ➝ Neutral	$53.00	Medium	i
8/17/2017	Cowen	Reiterated Rating	Buy	$55.00	Medium	i Rating by Josh Jennings at Cowen Inc
8/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$58.00	Low	i
7/22/2017	Barclays	Reiterated Rating	Overweight	$52.00 ➝ $57.00	Low	i
7/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$58.00	Low	i
7/14/2017	Cowen	Reiterated Rating	Outperform	$48.00 ➝ $55.00	Low	i Rating by Josh Jennings at Cowen Inc
7/11/2017	BMO Capital Markets	Reiterated Rating	Hold	$48.00	Low	i
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low	i
6/30/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$47.50 ➝ $54.00	Low	i
6/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$58.00	Low	i
6/29/2017	Guggenheim	Initiated Coverage	Buy	$58.00	Low	i
6/21/2017	BTIG Research	Reiterated Rating	Buy	$56.00	Low	i
6/16/2017	Jefferies Financial Group	Reiterated Rating	Buy	$55.00	Low	i
5/31/2017	Stifel Nicolaus	Boost Price Target	Buy	$49.00 ➝ $51.00	Medium	i
5/16/2017	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$45.00	Low	i
5/15/2017	Royal Bank of Canada	Reiterated Rating	Buy		Low	i
5/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$50.00 ➝ $51.00	Low	i
4/22/2017	Cowen	Reiterated Rating	Outperform	$48.00	Medium	i Rating by Josh Jennings at Cowen Inc
4/20/2017	Barclays	Boost Price Target	Overweight ➝ Overweight	$50.00 ➝ $52.00	Low	i
4/19/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$42.00	Low	i
4/18/2017	UBS Group	Reiterated Rating	Neutral	$41.00	N/A	i
4/18/2017	Jefferies Financial Group	Lower Price Target	Buy	$52.00 ➝ $50.00	Medium	i
4/18/2017	Stifel Nicolaus	Reiterated Rating	Buy	$49.00	Medium	i
4/13/2017	Cowen	Reiterated Rating	Buy	$48.00	Low	i Rating by Josh Jennings at Cowen Inc
3/14/2017	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$48.00	Medium	i
3/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$51.00 ➝ $52.00	N/A	i
3/1/2017	Royal Bank of Canada	Boost Price Target	Outperform	$46.00 ➝ $50.00	N/A	i
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy	$51.00	N/A	i
1/26/2017	Royal Bank of Canada	Lower Price Target	Outperform	$48.00 ➝ $46.00	N/A	i
1/20/2017	Jefferies Financial Group	Boost Price Target	Buy	$47.00 ➝ $48.00	N/A	i
1/13/2017	Jefferies Financial Group	Boost Price Target	Buy	$46.00 ➝ $47.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
12/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$46.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/19/2016	Bank of America	Reiterated Rating	Buy		N/A	i
9/19/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$48.00	N/A	i Rating by Glenn Novarro at Royal Bank of Canada
9/13/2016	Jefferies Financial Group	Lower Price Target	Buy	$52.00 ➝ $48.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/12/2016	Bank of America	Reiterated Rating	Buy	$50.00	N/A	i
8/10/2016	BTIG Research	Reiterated Rating	Buy	$45.00	N/A	i Rating by Dane Leone at BTIG Research
8/9/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A	i Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
8/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$49.00 ➝ $52.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/28/2016	Argus	Reiterated Rating	Buy	$55.00	N/A	i
7/21/2016	Barclays	Boost Price Target	Overweight	$48.00 ➝ $50.00	N/A	i Rating by Matthew Taylor at Barclays PLC
7/21/2016	UBS Group	Reiterated Rating	Hold	$45.00	N/A	i
7/14/2016	Jefferies Financial Group	Boost Price Target	Buy	$45.00 ➝ $49.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/12/2016	Barclays	Reiterated Rating	Overweight	$48.00	N/A	i Rating by Matthew Taylor at Barclays PLC
6/21/2016	Edward Jones	Upgrade	Hold ➝ Buy		N/A	i
6/18/2016	Barclays	Reiterated Rating	Buy	$48.00	N/A	i Rating by Matthew Taylor at Barclays PLC
6/14/2016	Jefferies Financial Group	Boost Price Target	Buy	$44.00 ➝ $45.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/8/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Matthew Keeler at Credit Suisse Group AG
5/13/2016	Jefferies Financial Group	Reiterated Rating	Buy	$44.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/12/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i Rating by Larry Biegelsen at Wells Fargo & Company
5/2/2016	BMO Capital Markets	Reiterated Rating	Buy		N/A	i
4/30/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
4/30/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Matthew Keeler at Credit Suisse Group AG
4/30/2016	S&P Equity Research	Reiterated Rating	Hold		N/A	i Rating by Jeffrey Loo at S&P Equity Research
4/30/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i Rating by Larry Biegelsen at Wells Fargo & Company
4/30/2016	Gabelli	Reiterated Rating	Buy		N/A	i Rating by Jennie Tsai at Gabelli
4/28/2016	BTIG Research	Reiterated Rating	Buy	$45.00	N/A	i Rating by Dane Leone at BTIG Research
4/28/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral		N/A	i
4/21/2016	Cowen	Reiterated Rating	Neutral ➝ Buy	$44.00 ➝ $48.00	N/A	i Rating by Josh Jennings at Cowen Inc
4/20/2016	BTIG Research	Reiterated Rating	Buy	$45.00	N/A	i Rating by Dane Leone at BTIG Research
4/17/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Matthew Keeler at Credit Suisse Group AG
4/14/2016	First Global	Downgrade	Outperform ➝ Marketperform		N/A	i Rating by K. Thomas at First Global
4/11/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$45.00 ➝ $48.00	N/A	i
3/28/2016	Stifel Nicolaus	Boost Price Target	Buy	$42.00 ➝ $47.00	N/A	i
3/28/2016	SVB Leerink	Boost Price Target	Market Perform	$37.00 ➝ $40.00	N/A	i
3/28/2016	BMO Capital Markets	Boost Price Target	Outperform	$42.00 ➝ $45.00	N/A	i
3/19/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A	i Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
3/16/2016	BTIG Research	Reiterated Rating	Buy	$45.00	N/A	i Rating by Dane Leone at BTIG Research
3/15/2016	Jefferies Financial Group	Reiterated Rating	Buy	$45.00 ➝ $47.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
3/15/2016	Credit Suisse Group	Reiterated Rating	Outperform	$47.00	N/A	i

(Data available from 2/24/2016 forward)

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $122.38

$120.66

$122.91

50 Day Range

MA: $118.58

$108.84

$128.23

52 Week Range

Now: $122.38

$61.61

$128.54

Volume

4,124,722 shs

Average Volume

5,351,730 shs

Market Capitalization

$216.80 billion

P/E Ratio

64.75

Dividend Yield

1.49%

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

The following sell-side analysts have issued reports on Abbott Laboratories in the last year: Argus, Bank of America Co., Barclays PLC, BTIG Research, Cfra, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for ABT.

What is the current price target for Abbott Laboratories?

18 Wall Street analysts have set twelve-month price targets for Abbott Laboratories in the last year. Their average twelve-month price target is $121.83, suggesting a possible downside of 0.4%. BTIG Research has the highest price target set, predicting ABT will reach $140.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $94.00 for Abbott Laboratories in the next year.
View the latest price targets for ABT.

What is the current consensus analyst rating for Abbott Laboratories?

Abbott Laboratories currently has 1 sell rating, 1 hold rating and 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABT will outperform the market and that investors should add to their positions of Abbott Laboratories.
View the latest ratings for ABT.

What other companies compete with Abbott Laboratories?

Other companies that are similar to Abbott Laboratories include Medtronic, Stryker, Intuitive Surgical, Becton, Dickinson and, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Baxter International, DexCom, ResMed, Hologic, Teleflex, Insulet, Varian Medical Systems and STERIS.

How do I contact Abbott Laboratories' investor relations team?

Abbott Laboratories' physical mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker's listed phone number is 224-667-6100. The official website for Abbott Laboratories is www.abbott.com.

NYSE:ABT - Abbott Laboratories Stock Price Target and Predictions

Analyst Price Target for ABT

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

What is the current price target for Abbott Laboratories?

What is the current consensus analyst rating for Abbott Laboratories?

What other companies compete with Abbott Laboratories?

How do I contact Abbott Laboratories' investor relations team?